PHGG vs Tirzepatide

Head-to-head evidence comparison — which supplement is right for you?

Quick answerNo interaction data — ask a pharmacist

PHGG vs Tirzepatide: Tirzepatide has the stronger overall evidence (7.8 vs 6/10); the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.

Tirzepatide Edges Ahead

Tirzepatide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.

PHGG1 win

Tirzepatide2 wins

Which is right for you? Take the 60-second quiz Open in the full comparison tool

Pg6.0

PHGG

Too few graded studiesHigh safety

Tir7.8

Tirzepatide

Too few graded studiesLimited safety

Evidence

Evidence Score

6/10

Studies: 34

Meta-analyses: 3

Level: Moderate

Evidence Score

Best7.8/10

Studies: 133

Meta-analyses: 42

Level: Strong

Research findings

Verdict

Too few graded studies

Top outcomes

Digestive healthToo few graded studies27
Weight managementMostly mechanism / observational3
Therapeutic & clinicalToo few graded studies3

Verdict

Too few graded studies

Top outcomes

Weight managementToo few graded studies80
Glycemic & metabolic controlToo few graded studies53
Heart & blood pressureToo few graded studies20

Shared outcomes (1)

Outcomes where both PHGG and Tirzepatide have evidence — compare verdict strength side-by-side.

Weight managementMostly mechanism / observational3Too few graded studies80

Dosage & timing

Recommended Dosage:

5-6g daily

Warnings

Start with lower dose to assess tolerance
Drink adequate water with fiber

Best Time:

With meals, Can be added to drinks or food

Take with food

Best Form:

PHGG powder (Sunfiber is common brand)

Recommended Dosage:

Once-weekly subcutaneous injection, started at 2.5 mg and escalated by 2.5 mg every 4 weeks to a maintenance dose of 5, 10, or 15 mg (per the prescribing physician and approved indication)

Warnings

PRESCRIPTION DRUG — this is an FDA-approved medication (Mounjaro / Zepbound), not a dietary supplement. Use only under medical supervision for an approved indication.
US FDA labeling includes a boxed warning about thyroid C-cell tumors: tirzepatide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.
Pancreatitis has been reported — discontinue and seek care for severe, persistent abdominal pain; avoid in those with a pancreatitis history.
Gallbladder disease (gallstones, cholecystitis) can occur, partly related to rapid weight loss.
Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are common, especially during dose escalation.
A portion of the weight lost is lean (muscle) mass — prioritize adequate protein and resistance exercise.
FDA has warned about compounded and grey-market tirzepatide of unverified identity, purity, and dose — do not source outside a legitimate prescription.
Not for cosmetic or off-label use without a medical indication and supervision.
May reduce the efficacy of oral contraceptives via delayed gastric emptying — use a backup method when starting and after dose increases.
Benefits depend on continued use — randomized withdrawal data show substantial weight regain after stopping.

Best Time:

Any time of day

Can take on empty stomach

Best Form:

Once-weekly subcutaneous injection (Mounjaro / Zepbound)

Safety

High safetyBest

Drug Interactions:

Oral medications (mild)

Side Effects:

Initial gas

Contraindications:

Known allergy or hypersensitivity to PHGG or related compounds

Limited safety

Drug Interactions:

Oral contraceptives (moderate)
Insulin and sulfonylureas (moderate)
Oral medications generally (moderate)

Side Effects:

NauseaDiarrheaVomiting

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC) (a contraindication under the US label)
Multiple endocrine neoplasia syndrome type 2 (MEN2) (a contraindication under the US label)

What you'll notice

✓ Improved Regularitypositive

1-2 weeks

😌 IBS Symptom Reliefpositive

2-4 weeks

🦠 Microbiome Supportpositive

2-4 weeks

🩸 Strong glycemic controlpositive

Weeks to months

⚖️ Large weight losspositive

Months (dose-escalated over ~20 weeks)

😴 Reduced sleep-apnea severitypositive

Weeks to months

🤢 GI side effects (common)negative

Mostly during titration

Key studies

Effectiveness of Partially Hydrolyzed Guar Gum on Cognitive Function and Sleep Efficiency in Healthy Elderly Subjects in a Randomized, Double-Blind, Placebo-Controlled, and Parallel-Group Study

Nutrients (2024) · Rct

The visual memory scores in cognitive function tests and sleepiness on rising scores related to sleep quality were significantly improved in the PHGG group compared to the placebo group.

Continuous partially hydrolyzed guar gum intake reduces cold-like symptoms: a randomized, placebo-controlled, double-blinded trial in healthy adults

European review for medical and pharmacological sciences (2022) · Rct · n=96

Double-blind RCT in 96 healthy Japanese adults given 5.2 g PHGG or placebo daily for 12 weeks.

Prebiotic Effects of Partially Hydrolyzed Guar Gum on the Composition and Function of the Human Microbiota-Results from the PAGODA Trial

Nutrients (2020) · Open label · n=20

To gain functional insight, we further studied stool metabolites using nuclear magnetic resonance (NMR) spectroscopy. (3) Results: In healthy subjects, PHGG had significant effects on stool frequency and consistency.

All PHGG studies

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

N Engl J Med (2021) · Rct · n=1879

Open-label 40-week phase-3 head-to-head RCT (SURPASS-2) in 1879 patients with type 2 diabetes, tirzepatide 5/10/15 mg vs semaglutide 1 mg

Tirzepatide Once Weekly for the Treatment of Obesity.

N Engl J Med (2022) · Rct · n=2539

72-week phase-3 double-blind RCT (SURMOUNT-1) in 2539 adults with obesity (without diabetes), tirzepatide 5/10/15 mg vs placebo

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.

N Engl J Med (2025) · Rct · n=751

Phase-3b open-label head-to-head RCT (SURMOUNT-5) in 751 adults with obesity but without diabetes, max-tolerated tirzepatide vs max-tolerated semaglutide

All Tirzepatide studies

Dose-response curve

PHGG

EffectivenessSide effect riskOptimal

Both points come from one multicentre open trial in IBS patients that gave 5 g a day (46 patients) or 10 g a day (40 patients) for 12 weeks (PMID 15986863). Symptoms and quality of life improved from baseline in both groups, with no better result reported at 10 g, and the gain faded by the 6-month follow-up. The trial had no placebo group, so the size of the effect over placebo is unknown. Lower and higher doses were not tested, so no optimal dose or safety ceiling can be read from it.

Tirzepatide

No dose-response data

AI-estimated from published studies. Interpret as directional guidance.

Frequently asked questions

Is PHGG better than Tirzepatide?

Tirzepatide has a higher evidence score (7.8/10 vs 6/10) and wins in 2 of 3 categories.

Can I take PHGG and Tirzepatide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.

Related comparisons

PHGG vs Semaglutide Liraglutide vs PHGG PHGG vs Thiamine Semaglutide vs Tirzepatide Liraglutide vs Tirzepatide Thiamine vs Tirzepatide

Still deciding between PHGG and Tirzepatide?

The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.

Get your personalised pick PHGG details Tirzepatide details

Warnings

PRESCRIPTION DRUG — this is an FDA-approved medication (Mounjaro / Zepbound), not a dietary supplement. Use only under medical supervision for an approved indication.

US FDA labeling includes a boxed warning about thyroid C-cell tumors: tirzepatide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.

Pancreatitis has been reported — discontinue and seek care for severe, persistent abdominal pain; avoid in those with a pancreatitis history.

Gallbladder disease (gallstones, cholecystitis) can occur, partly related to rapid weight loss.

Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are common, especially during dose escalation.

A portion of the weight lost is lean (muscle) mass — prioritize adequate protein and resistance exercise.

FDA has warned about compounded and grey-market tirzepatide of unverified identity, purity, and dose — do not source outside a legitimate prescription.

Not for cosmetic or off-label use without a medical indication and supervision.

May reduce the efficacy of oral contraceptives via delayed gastric emptying — use a backup method when starting and after dose increases.

Benefits depend on continued use — randomized withdrawal data show substantial weight regain after stopping.